Solutia Reports Third Quarter 20...($3734 ...)

Date:10/26/2009

$3,734 ====== ====== LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities: Accounts payable $139 $170 Accrued liabilities 203 259 Short-term debt, including current portion of long-term debt 31 37 Liabilities of discontinued operations 58 302 --- --- Total Current Liabilities 431 768 Long-Term Debt 1,167 1,359 Postretirement Liabilities 443 465 Environmental Remediation Liabilities 262 279 Deferred Tax Liabilities 189 202 Other Liabilities 107 132 Commitments and Contingencies (Note 9) Shareholders' Equity : Common stock at $0.01 par value; (500,000,000 shares authorized, 121,864,293 and 94,392,772 shares issued in 2009 and 2008, respectively) 1 1 Additional contributed capital 1,608 1,474 Treasury shares, at cost (417,517 in 2009 and 77,132 in 2008) (2) -- Accumulated other comprehensive loss (216) (286) Accumulated deficit (788) (668) ----- ----- Total Shareholders' Equity attributable to Solutia 603 521 Equity attributable to non-controlling interest 6 8
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Solutia Reports First Quarter 2009 Results
2. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
3. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
4. NuVasive Reports Third Quarter 2009 Financial Results
5. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
8. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
9. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
10. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009